In vitro studies of 223Ra- and 225Ac-labelled α-zirconium phosphate as potential carrier for alpha targeted therapy

In this study suitability of α-ZrP nanoparticles as a 223Ra and 225Ac carriers for TAT was investigated. The yields of radiolabelling were higher than 98% in both cases. Subsequently, in vitro stability studies were carried out in various biological matrices during 48 h period. Measurements of released radioactivity showed the highest stability in saline. Released activity of 223Ra, 225Ac and their daughter radionuclides was around 0.5%. On the other hand, the lowest stability was shown in plasma and serum. Released activity for 223Ra, 225Ac and their progeny atoms was from 15 to 32%.